When we first met Will Yin and Rohit Rustagi, it was clear that they were obsessed with solving an urgent problem in healthcare: closing the time-to-access for specialty therapies that treat conditions like cancer and Alzheimer’s.
In our meeting, Will articulated how he could build “a new kind of worker for healthcare.” One that could log in, pick up the phone, fill out a form, and ultimately help patients get access to specialty pharmaceuticals in a fraction of the time.
It was an idea rooted in experience. Both Will and Rohit had family members struggle to access specialty therapies for conditions like cancer and Alzheimer’s — the types of drugs that cost hundreds of thousands of dollars and take weeks or months to approve (if they’re approved at all). These are powerful, personalized therapies, but the workflows to deliver them are stuck in the past. Clinics, health systems, and pharmacies lose weeks navigating approvals, reading policy documents, and chasing reimbursement — all while patients wait for treatment.
And the problem is only growing. Specialty drugs now account for over half of U.S. prescription spend and are 75% of the FDA drug pipeline. The healthcare system can’t keep up.
Mandolin is solving for this, with its AI automation platform for specialty drug access. We at Greylock are privileged to partner with Will and Rohit and lead the company’s Series A investment.
Mandolin’s AI agents act like full-time employees — reading, reasoning, and completing tasks across systems. From benefits verification to prior auth and billing, it’s not a tool but a workforce. One that works 24/7, scales effortlessly, and delivers higher accuracy than traditional workflows.
And it’s working. Since launching their agents in January, Mandolin is already live with some of the largest infusion providers, specialty pharmacies, and health systems in the country, including Vivo, FlexCare, OI Infusion, and TwelveStone. It’s deployed at 700+ clinics and serves over 250,000 new patients annually. Teams are cutting days of administrative work down to hours, increasing revenue, reducing manual overhead, and getting patients on therapy weeks sooner than before.
Some of the most thoughtful founders we’ve worked with didn’t initially set out to build companies, but encountered a problem they just had to solve. Will spent his high school and college years publishing neuroscience research and preparing for a career as a physician-scientist. Rohit, a Fulbright awardee, studied bioethics and entered med school at Stanford. They each walked away from medicine — not because they lost faith in science, but because they realized the real bottleneck was the system and the timing was right to make a real impact.
The emergence of multi-agent AI platforms finally has the tooling to automate complex workflows end-to-end. As Mandolin builds the definitive AI teammate for the largest health systems in the world, we’re proud to support Will, Rohit, and team as they turn AI into a force that helps more people access the care they need, when they need it. If you’re interested in this mission, Mandolin is hiring!
